





## COVID-19 DAY 206 LFC UPDATE


OCTOBER 2, 2020 SECRETARY DAVID R. SCRASE, M.D.

INVESTING FOR TOMORROW, DELIVERING TODAY.

### LEADERSHIP, SCIENCE & GOOD JUDGMENT

- During early stage of pandemic, non-peerreviewed research (also known as preprints) represented nearly 40% of all Englishlanguage COVID-19 scientific literature.
- As a result, NM had to start from scratch and make critical and timely policy decisions based on virtually no scientific evidence.
- We prefer strong scientific evidence to support every policy decision, but such data is not always available. When we have sound and reliable scientific evidence, we use it, every time.
- Throughout the pandemic, the Medical Advisory Team has provided a critical role in sifting through the "noise" in scientific literature; and, in cases where evidence is lacking, using their experience and clinical judgement to develop material for the State to consider.

Graph 2: Stack Chart - Monthly Distribution of Preprint's Publication Status (raw)



## NEW MEXICO MEDICAL ADVISORY TEAM (MAT)

- In accordance with 2018 New Mexico Crisis Standards of Care Plan and declaration of the Public Health Emergency, NMDOH activated the MAT, which serves as a science and medical advisory group to DOH to:
  - Facilitate Coordination and Planning
  - Develop recommendations, Guidelines or Protocols
  - Provide guidance
  - Prepare to address emerging questions
  - Source for expert opinion
  - Source for identification of resources
- Over 170 participants at peak activity, including state staff, healthcare providers, public health practitioners, data analysts, and legal/ethical experts.

- State of New Mexico also organized entities to address economic aspects resulting from the COVID-19 pandemic, including:
  - Mayor's Council: bipartisan group of mayors from across the state advises the State on plans to reopen New Mexico's economy. Council members working with business owners to ensure they adopt COVID-safe practices to minimize the potential for renewed outbreaks of the disease.
  - Economic Recovery Council: diverse group of business and labor leaders from across New Mexico advising the State on strategies for safely reopening New Mexico businesses. Includes leaders from tech industries, tourism and hospitality, film, construction, energy, agriculture and locally-based retail.



Hospital & Health System

Clay Holderman (Chair)

Troy Greer, Lovelace

Kate Becker, UNMH Lillian Montoya, CHRISTUS David Canejo, RMCHS Jeff Bourgeios, SJRMC

Derrick Cuenca, MVRMC

Caryn Iverson, MMC


Leonard Thomas, ABQ Area

Operations

-MAT Committee Leads

-HHS Advisory Chair

-DOH Leadership Team



## NM MEDICAL ADVISORY TEAM (MAT)

### MAT's 50 public documents organized using tags below:

- Behavioral Health
- Children & Youth
- Clinical Care
- Drugs & Therapeutics
- Nursing Facilities/Long-term Care
- Personal Protective Equipment (PPE)
- Public Health
- Regional Care Coordination
- Reopening Healthcare
- Testing
- Workforce

#### **MAT Resources**

#### **COVID-19 Frequently Asked Questions**

Sep 14, 2020 | MAT Resources

This document outlines a series of responses to COVID-19 frequently asked questions, including information about finding New Mexico COVID-19 cases by county, risk of transmission in certain settings (e.g. dining, gyms), and COVID-19 deaths. Download this resource

#### Chloroquine or hydroxychloroquine not recommended for treatment of COVID-19

Aug 31, 2020 | MAT Resources

The Medical Advisory Team no longer recommends chloroquine and hydroxychloroquine for the treatment of COVID-19 or SARS-CoV-2 infection, with or without azithromycin. Download this resource

## Recommendations for Long-Term Care Facilities related to Facility Transfers and Care Coordination for COVID-19 Positive (and Negative) Residents

Aug 24, 2020 | MAT Resources

The MAT outlines recommendations for Skilled Nursing Facilities, Long-Term Care Facilities, and Assisted Living Facilities related to managing patients/residents who are moving betweenfacilities, including for ancillary and emergency care. Detailed guidance also is...

Date: August 20, 2020

### SAMPLE OF RECENT MAT RESOURCES

- COVID-19 Frequently Asked Questions
- Chloroquine or hydroxychloroquine not recommended for treatment of COVID-19
- Recommendations for Long-Term Care Facilities related to Facility Transfers and Care Coordination for COVID-19 Positive (and Negative) Residents
- Review of Current SARS-CoV-2 Test Methods and Recommendations for Increasing Testing Capacity in New Mexico
- Use of ivermectin in the treatment of COVID-19
- Prioritization of Remdesivir Distribution & Treatment for COVID-19 (Revised)
- Mask Guidelines for Children and Youth (Revised)
- COVID-19 Children & Youth Frequently Asked Questions (Revised)
- Long-term Facility Resident Cohorting Recommendations
- Phase 1 Reopening Guidelines for Dental Care Settings (Revised)

#### New Mexico Medical Advisory Team - Testing Group

#### Review of Current SARS-CoV-2 Test Methods and Recommendations for Increasing Testing Capacity in New Mexico

Executive Summary	
SARS-CoV-2 COVID Rapid Diagnostic Tests Criteria for review:	
Rapid Molecular Tests	
Rapid Antigen Tests	
Routine Molecular Diagnostic Tests	
Respiratory Virus Season Planning Multiplex Testing Platforms	(
Pooling	
Testing Capacity	
Summary Chart	

#### **Executive Summary**

Over the past several months new data has emerged for existing and expanding test methods for detection of SARS-CoV-2. This document provides a summary and recommendation for some of these methods.

- Rapid molecular point of care tests have emerged and offer significant improvement for near
  patient turn-around-time. Although early data showed challenges for the Abbott ID Now, the
  current data demonstrate that the ID Now (rapid molecular) and rapid antigen tests have value in
  symptomatic patients within the first week of symptom onset.
- Alternative specimen types to the nasopharyngeal swab are helpful in reducing the need for PPE during aerosol generating procedures, but do not increase test capacity.
- Pooling is a valuable tool to increase test capacity, but FDA regulatory requirements present challenges for laboratories.
- The addition of SARS-CoV-2 to multiplex tests offer helpful diagnostic tools for use during respiratory virus season.

Recommendation for maximizing and aligning testing methods are included below for each method. In addition, the Medical Advisory Team recommends the following:

- 1. Maximize the existing testing capabilities in the state via:
  - Maximize testing reagent allocations to all platforms via multi-state consortia, modified federal allocations, additional commercial contracts, or other methods
  - Identify other rate-limiting elements to the maximize the existing platform capacity at state, hospital and commercial laboratories and address accordingly (e.g. increased space, staffing equipment, expertise, etc.)
- Develop a statewide pooling strategy to efficiently process low-prevalence populations. This may require added resources from the state directed to a small number of testing centers.
- 3. Enhance Point of Care testing capacity in the state, being mindful of upcoming flu season demands:

## COMPLETED MAT INQUIRIES


1.	PPE for a single average nospitalization, by type		
2.	Testing methods overview, effectiveness, and availability	27.	Resumption of medically necessary procedures: medical offices
3.	What is the role of BiPAP and CPAP in treatment of COVID?	28.	Resumption of medically necessary procedures: surgeries and hospita
4.	Number of ventilators NM have on-hand, and approval for sale	20	procedures
5.	Remdesivir Treatment Recommendations	29.	Public health gating criteria
6.	Review of travel order	30.	COVID-19 safe practices for all New Mexicans
		31.	Antibody messaging for clinicians
7.	Review of Wonfo test kit	32.	Antibody messaging for providers
8.	Review of Gibson proposal, and Hilton Gardens	33.	Antibody testing overview and state recommendations
9.	Review of DOH on-line screening tool	34.	Standardized Treatment Guidelines for acute care facilities
10.	PPE recommendations for ICF's/IID's	35.	Guidelines for treatment of COVID-19 associated coagulopathies
11.	PPE for stockpile, PPE burn rate, sterilization, prioritization, 3D-printed PPE feasibility	36.	Use of hydroxychloroquine (HCQ) for treatment of COVID-19
12.	Review of COVID-only hospital	37.	Use of BH Agencies for COVID-19 test sites
13.	Equipment list for MFS	38.	Pediatric testing
14.	Appolo-19 awareness for the Governor	39.	Remdesivir distribution
	• •	40.	PPE State stockpile distribution
15.	Cloth masks effectiveness	41.	Choir singing restrictions
16.	Should NM obtain hydroxychloroquine sulfate for treatment?	42.	PPE Reprocessing guidance
17.	Tracking intubation drug supply	43.	Pediatric Inflammatory Syndrome guidance
18.	Provisions for people who may experience dangerous levels of alcohol withdrawal	44.	Pediatric masking guidance
19.	mLife DX COVID test kits offer	45.	COVID-19 testing
20.	Deployment of mobile PPE sterilization unit	46.	Mask related disability accommodations
21.	AirLock389 Anti-Viral N8 Mask validity	47.	Abbott ID NOW validity
22.	Election preparedness	48.	Long-term care data collection
23.	Public health practice implications for COVID-19 in children	49.	Strategies to increase PPE supply and decrease consumption
24.	Relaxing requirements for Pas and podiatrists	50.	How to define recovered cases
25.	Evaluation of vents and kits offered by Odyssey	51.	Series of recommendations related to long-term care facilities
25.	LValuation of vents and kits onered by Odyssey		


MAT Call Center recommendation

### COMPLETED MAT INQUIRIES


- 52. Phase 1 Reopening Guidelines for Dental Care Settings (Revised)
- 53. Literature and Online Resources on Interventions to Support Residents of Long-Term Care Facilities Experiencing Social Isolation, Failure to Thrive, and Cognitive Impairment
- 54. Recommended Activities for Residents of Long-Term Care Facilities Designed to Mitigate Feelings of Social Isolation
- 55. COVID-19 Best Practices across NM Long-term Care Facilities
- 56. Prioritization of Remdesivir Treatment among COVID-19 Patients
- 57. Antibody testing guidelines for healthcare providers
- 58. COVID-19 Antibody testing guidelines for the public
- 59. COVID-19 Antibody testing overview
- 60. Recommendations for Long-Term Care Facilities re: Facility Transfers and Care Coordination for COVID-19 Positive (and Negative) Residents
- 61. COVID-19 Contingency Operational Spaces & Practices currently provided for by waivers
- 62. Current and recommended programs
- 63. LTC Facility Visitation Review of States
- 64. Side by side data collection comparison
- 65. State Actions for COVID Management and Response
- 66. Long-term care visitation guidance
- 67. Ivermictin as treatment for COVID-19
- 68. Review of Current SARS-CoV-2 Test Methods and Recommendations for Increasing Testing Capacity in New Mexico
- 69. Addressing behavioral health needs of New Mexicans
- 70. Chloroquine or hydroxychloroquine not recommended for treatment of COVID-19
- 71. Frequently Asked Questions
- 72. Recommendations regarding resumption of youth sports

# COVID-19 IN NM UPDATE







### Total COVID-19 Positive Cases (9/30/2020) 14-Day Total of New COVID-19 Positive Cases 11 (9/17 to 9/30)



Source: New Mexico Department of Health. \* denotes new death occurred in county. Excludes cases in federal and state detention facilities.



# NM COVID-19 Daily Cases by Specimen Collection Date, Hospitalizations, and Deaths 7 Day Rolling Average




# GATING CRITERIA UPDATE

# STATEWIDE PUBLIC HEALTH GATING CRITERIA FOR REOPENING 15

Criterion	Measure	Gating Target	Current Status
Spread of COVID-19 Rate of COVID-19 Transmission (10-day Rolling Average)		1.05 or less	1.27 on 9/30/20
	NM daily cases (7-day rolling average)	168	171 on 9/25/20
Testing Capacity: general	Number of tests per day (7-day rolling average)	5,000 / day	6,086 on 9/29/20
populations*	nd targeted opulations* Test Positivity Rate (7-day rolling average)		3.24% on 9/29/20
Contact Tracing and			
Isolation Capacity	-isolation recommendation for case -quarantine rec. for case contacts	24 hrs 36 hrs	Week ending 9/25= 20 Week ending 9/25 = 23
Statewide Health Care	Availability of scarce resources in 7 Hub Hospitals:		
System Capacity	-Adult ICU beds occupied	439 or less	236 on 10/1/20
	-PPE	7-day supply	7 on 9/26/20


#### ALL 4 CRITERIA DRIVEN BY SOCIAL DISTANCING BEHAVIORS OF NEW MEXICANS

## How we reopen safely



Notes: If a @is next to a state it indicates a state-wide mandated mask policy for indoor AND outdoor settings. For detailed definitions see: https://www.covidexitstrategy.org/definitions-and-criteria


Table: covidexitstrategy.org • Source: Multiple Sources (NYT, COVID Tracking Project, rt.live, ILI, CDC) • Get the data • Created with Datawrapper



COVID-19 Average Daily Case Rates by Test Positivity, New Mexico Counties, September 15 - September 28, 2020


Graphic credits: (left, NM Dept. of Health; right, Los Alamos National Lab)

# Percentage of Persons Tested for SARS-CoV-2 by County, New Mexico as of 9/27/20, (%)



### MODELING IMPACT OF COVID-19 IN NM

- Model is developed in partnership with Presbyterian Health Services, Los Alamos National Laboratory, and NM Department of Health.
- Model incorporates a variety of near real-time data, including:
  - COVID-19 case information.
  - State-wide testing rates.
  - Geographic distribution of cases and testing.
  - Clinical outcomes including hospitalization, intensive care, and mechanical ventilation.
  - Healthcare system resource capacity and demand.
  - Differences in disease risk using comprehensive data on social determinants of health, Johns Hopkins Adjusted Clinical Groups, and health plan claims data.





#### MAT MODELING TEAM

- As understanding of novel coronavirus grows, NM uses modeling to help close gaps in knowledge and better ensure we're meeting goals in areas related to:
  - Public health gating criteria for reopening;
  - School reopening;
  - Reopening of the economy; and,
  - COVID-19 shelter capacity.
- MAT Modeling team instrumental in identification of (and setting targets for) gating criteria.
- NM early adopter of gating criteria (<u>currently</u> in use by 36 states and territories, including DC).

Public Health Gating Criteria for Reopening NM  Click here to view the NM Current Case Outlook							
Category	Measure	Target	Current Status	Status Updated Each:			
Spread of COVID-19	<ol> <li>Rate of spread (10-day rolling average)</li> </ol>	1.05 or less	1.23	Mon, Wed, Fri			
Spread of COVID-19	<ol><li>NM daily cases (7-day rolling average)</li></ol>	168	159	Mon, Wed, Fri			
Testing Capacity (general and vulnerable populations)*	<b>3.</b> Number of COVID-19 tests per day (7-day rolling average)	5,000	6,086	Mon, Wed, Fri			
Testing Capacity (general and vulnerable populations)*	<b>4.</b> COVID-19 test positivity rate (7-day rolling average)	5.00% or less	3.2%	Mon, Wed, Fri			
Contact Tracing and Isolation Capacity	<b>5.</b> Time from COVID-19 positive test result to case isolation	24 hours or less	20 hours	Tues			
Contact Tracing and Isolation Capacity	<b>6.</b> Time from COVID-19 positive test result to quarantine of case contacts	36 hours or less	23 hours	Tues			
Statewide Healthcare System Capacity	7. Adult ICU beds occupied across 7 NM Hub Hospitals**	less than 439	233	Tues			
Statewide Healthcare System Capacity	8. 7-day supply of personal protective equipment (PPE) across 7 NM Hub Hospitals**	7-day supply in at least 6 out of 7 Hub Hospitals	7 out of 7 hospitals	Tues			







# COMMENTS AND QUESTIONS

SECRETARY DAVID R. SCRASE, M.D.

INVESTING FOR TOMORROW, DELIVERING TODAY.